Those who attended the June 4 Advisory Council meeting came away with interesting and important information, courtesy of NIAID Director Dr. Anthony Fauci and guest speaker Dr. John Mascola, director of the NIAID Vaccine Research Center.
NIAID issued a contract solicitation seeking proposals that possess the research and development expertise necessary to carry out research that helps meet two key program objectives of NIAID’s Division of Microbiology and Infectious Diseases.
Help develop new and innovative sustained/extended release drugs and drug delivery systems that can achieve extended durations of HIV prevention in at-risk individuals.
The Rare Diseases Clinical Research Consortia (RDCRC) advance diagnosis, management, and treatment of rare diseases with a focus on clinical trial readiness. Each RDCRC center promotes highly collaborative, multi-site, patient-centric, translational and clinical research.
Consider this preclinical/nonclinical opportunity if your research interests include understanding tuberculosis meningitis pathogenesis and its treatment in the presence or absence of HIV.
NIAID will no longer accept for review any competitive renewal T32 or T35 application that principal investigators submit more than 18 months before the project end date of a current noncompeting award.
NIAID seeks your input as we develop a strategic framework to advance tuberculosis research and development for the next five years and beyond.
Learn how the SAM registration and renewal process has changed in recent months and how that led to an exception (since expired) to NIH's late application policy.
Whether you’re a postdoc or junior faculty, consider applying for a mentored career development (K) award from NIAID. Our analyses show a correlation between K awards and future success rates for independent NIH research awards.
The program seeks to identify scientists with high-impact ideas that may be risky or at a stage too early to fare well in the traditional peer review process.
This initiative funds innovative methods in Big Data Science to identify gaps in rare, unseen, and otherwise undiscovered biomedical, behavioral, social patterns, and other social determinants that shed light on HIV acquisition, transmission, and long-term control using Big Data Science.
Find tips and reminders: For example, for multiproject awards—you should provide inclusion enrollment reports at the level of the subproject and not associated with the parent grant.
The next NIH Regional Seminar will take place in San Francisco, California, from October 17 to 19, 2018. Register by next Friday, June 29, to receive an early bird discount.
Get a refresher on the timeline for an investigator-initiated R01 application and how that timing relates to the fiscal year's three review cycles.
Take advantage of an opportunity to introduce a collaborative cross mouse model into your projects to advance understanding of host genes involved in immune regulation and function, and determine whether such models can more faithfully reflect human immune responses.
Consider sending a proposal to become the next contractor for the NIAID Virology Quality Assurance Program, which provides a comprehensive quality assessment for laboratories performing virologic assays of HIV and other pathogens in clinical trials sponsored by NIAID's Division of AIDS.
Investigators, we want to hear about novel or non-traditional animal models that more closely mimic human immune responses to influenza infection or vaccination. These fresh models could aid research to develop a universal flu vaccine.
For applications proposing certain types of research, you need to know whether the NIH or FDA definition of a clinical trial takes precedence and if funded whether you should register your clinical trial at—and later submit your summary results information to—ClinicalTrials.gov.
NIAID is clarifying the scope of its funding opportunity announcement for small businesses proposing investigator-initiated clinical trials, describing Phase II/IIB and Fast-Track applications and delineating clinical trial planning tasks allowed as part of Fast-Track Phase I Specific Aims and unallowed clinical trial activities.
NIH’s Office of AIDS Research is collecting community feedback to aid development of its FY 2021-2023 Strategic Plan, which will provide information about NIH’s HIV/AIDS research priorities to the scientific community, Congress, community stakeholders, HIV-affected communities, and the broader public.
Certain codes in your summary statement can indicate an award restriction or bar to award, which block you from funding until you resolve scientific review concerns about human subjects involvement, human subjects inclusion, or animal welfare in your application.
NIH is launching the Human Subjects System (HSS) on June 9, which replaces the Inclusion Management System (IMS). Take one critical step before HSS launches to avoid possible delays for fiscal year 2018 awards.
Gain funding to support large-scale discovery of T cell immune epitopes associated with infectious or autoimmune diseases, commensal organisms, or alloantigens, as well as validation of these epitopes’ role in immune protection or immune-mediated pathogenesis in humans.
Calculating effort isn't an exact science, but you need to make an appropriate estimate. Make sure your budget justification includes enough information for reviewers to understand why you need the time you request and what you'll do with it.
The topic of a universal influenza vaccine is receiving much attention, so we want to turn yours to two opportunities that offer possible funding for vaccine-related research.
If you are capable of innovative research and development of biologic drugs that alone or with combination antiretroviral therapy can induce long-lasting HIV remission, apply for support under a new R01 funding opportunity.
Propose to develop and optimize delivery vehicles or cell-targeting strategies, in combination with an existing gene therapeutic strategy, using in vivo administration in an animal model context.
Records you complete in the Inclusion Management System before June 9, 2018, will automatically migrate to the Human Subjects System. Incomplete records, not yet submitted by the signing official to NIH, will not migrate.
Learn our plans to modify the DMID Vaccine and Treatment Evaluation Units (VTEU) program and implement a Leadership Group that will work in conjunction with the VTEU sites and be responsible for generating clinical trial protocols.
TB Portals is a unique resource—a web-based, open-access platform that contains data from tuberculosis (TB) patients in high-burden countries, especially those with multi-drug resistant TB.
Apply for an administrative supplement to expand your current award to develop a focus on Alzheimer’s Disease and its related dementias.
Using FORMS-D to submit your application will result in an error; don’t let the error message mislead you into thinking the funding opportunity itself is expired.
Institutions must ensure their investigators disclose foreign financial interests; that is, those funds received from foreign institutions of higher education or the government of another country.
You may not necessarily associate the word “team” with research, but it’s becoming increasingly important to have people with complementary skills and expertise working together to achieve a common research goal.
NIAID is especially interested in studies of HIV drug treatment and prophylaxis—including oral and injectable drugs, vaccines, and broadly neutralizing antibodies—and potential interactions with hormonal and surgical treatments.
The two-phased Program combines a period of research experience as a tenure-track investigator in NIH’s Intramural Research Program (IRP) with additional years of independent financial support either within the IRP or at an extramural research institution.
Research how initial and repeated natural influenza infections or influenza vaccinations shape infant and childhood immunity to future influenza exposures.
Apply if you can integrate biomedical and behavioral science research strategies to encourage more personalized approaches to therapy, increased patient adherence to drug dosing instructions, and compliance with screening and retesting recommendations.
NIH’s Center for Scientific Review (CSR) will shift the AIDS and Related Research integrated review group cluster of study sections to scientifically align with current and emerging areas of HIV/AIDS research.
We anticipate, but cannot guarantee, concept approval for an initiative on vector biology and immunology at NIAID’s June 2018 Advisory Council meeting, followed by a funding opportunity announcement this fall.